BELLANTONIO, Paolo
 Distribuzione geografica
Continente #
NA - Nord America 310
EU - Europa 107
AS - Asia 77
AF - Africa 6
OC - Oceania 1
SA - Sud America 1
Totale 502
Nazione #
US - Stati Uniti d'America 309
IT - Italia 42
SG - Singapore 31
IN - India 26
SE - Svezia 22
CN - Cina 15
IE - Irlanda 13
FI - Finlandia 9
BG - Bulgaria 6
DE - Germania 5
TG - Togo 5
ID - Indonesia 3
RO - Romania 3
UA - Ucraina 3
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AU - Australia 1
CA - Canada 1
DZ - Algeria 1
ES - Italia 1
GB - Regno Unito 1
IR - Iran 1
NL - Olanda 1
PL - Polonia 1
Totale 502
Città #
Fairfield 52
Chandler 30
Ashburn 25
Singapore 24
Houston 19
Woodbridge 19
Cambridge 17
Seattle 17
Dublin 13
Rome 13
Princeton 12
Beijing 11
Wilmington 10
Santa Clara 9
Helsinki 7
Plano 7
Norwalk 6
Sofia 6
Ann Arbor 5
Boston 5
Lawrence 5
Lomé 5
San Paolo di Civitate 5
Fasano 4
San Diego 4
Jakarta 3
Naples 3
New York 3
Andover 2
Falls Church 2
Millbury 2
Munich 2
Algiers 1
Altea 1
Boardman 1
Brisbane 1
Bühl 1
Chiampo 1
Dearborn 1
Duncan 1
Falkenstein 1
Federal 1
Fort Worth 1
Harbin 1
Mannheim 1
Newark 1
Pomezia 1
Prineville 1
Provo 1
Redwood City 1
Sandston 1
Southwark 1
Toronto 1
Warsaw 1
Totale 369
Nome #
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 91
Fingolimod vs dimethyl fumarate in multiple sclerosis. a real-world propensity score-matched study 73
Use of herbal remedies by multiple sclerosis patients. a nation-wide survey in Italy 68
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 50
the prevalence of ms in central italy 48
null 36
null 33
null 31
Prognostic indicators in pediatric clinically isolated syndrome 23
Evaluation of drivers of treatment switch in relapsing multiple sclerosis. A study from the Italian MS Registry 21
Relapse-associated worsening in a real-life multiple sclerosis cohort: The role of age and pyramidal phenotype 19
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study 17
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks 14
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study) 14
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis 13
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 5
Totale 556
Categoria #
all - tutte 1.917
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.917


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202064 0 0 0 0 0 7 15 10 11 9 9 3
2020/202142 4 3 1 0 3 0 0 9 4 5 3 10
2021/2022107 9 9 5 3 22 8 1 10 4 6 16 14
2022/2023109 20 21 4 12 17 2 5 7 12 0 3 6
2023/202476 4 8 2 7 3 8 8 5 3 18 3 7
2024/202579 5 5 9 19 26 15 0 0 0 0 0 0
Totale 556